Jade Biosciences (JBIO) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic overview and pipeline progress

• Focused on developing best-in-class therapeutics for autoimmune diseases, leveraging three assets licensed from Paragon Therapeutics and others.

• Lead program JADE101 targets IgA nephropathy with a selective anti-APRIL antibody, aiming for superior efficacy and convenience through high binding affinity and extended half-life.

• JADE101 completed phase I enrollment; data expected in the first half of 2025, with phase II patient dosing planned mid-year and data anticipated in 2027.

• JADE201, an anti-BAFF receptor antibody, is set for phase I in rheumatoid arthritis in Q2 2025, with broad potential across autoimmune indications.

• A third, undisclosed program is expected to enter the clinic in the first half of 2027, following a similar strategy of validated targets and improved profiles.

Market opportunity and competitive landscape

• IgA nephropathy represents a $10–40 billion market in the U.S. alone, with 60–75% of 170,000–205,000 patients eligible for treatment.

• Recent approvals and broad labels, such as Otsuka's sibeprenlimab, have expanded the eligible patient pool and set high pricing benchmarks ($360,000–$390,000/year).

• Selective anti-APRIL therapies are expected to become frontline, foundational treatments due to their disease-modifying potential and favorable safety profiles.

• JADE101 aims to differentiate through superior potency, longer dosing intervals (Q8 weeks), and patient convenience, targeting significant market share.

• Competitive advantage is based on ultra-high binding affinity, extended half-life, and a translational framework that predicts clinical efficacy from biomarker responses.

Clinical development and differentiation

• JADE101's phase I focuses on safety, tolerability, and biomarker responses, with success defined by deep, durable APRIL suppression and sustained IgA reduction for at least eight weeks.

• Convenience is a key driver; Q8 week dosing is expected to be a major differentiator for both patients and clinicians.

• Rapid progression to registrational studies is planned, leveraging detailed biomarker data to engage with regulators and accelerate timelines.

• JADE201 is designed to overcome limitations of first-generation B-cell depleters by combining deep peripheral and tissue B-cell depletion with BAFF signaling blockade.

• Phase I in RA will generate safety, PK/PD, and exploratory efficacy data, informing future indication selection across a potential $80 billion market.